Want to see IN:ANMOL full AI Analyst Report?
Anmol India Ltd. (ANMOL) AI Stock Analysis
Anmol India Ltd.
(NSE:ANMOL)
The score is held back primarily by weaker financial quality—especially highly volatile cash generation and an uneven leverage profile—despite decent revenue scale. Technicals are a key positive with a strong uptrend and positive MACD, though momentum is stretched. Valuation is supportive with a low P/E, but limited by the absence of dividend-yield data.
Anmol India Ltd. (ANMOL) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 634.02M
- Dividend Yield
- ―
- Average Volume (3M)
- 26.09K
- Price to Earnings (P/E)
- 5.5
- Beta (1Y)
- 0.81
- Revenue Growth
- -2.63%
- EPS Growth
- 32.25%
- Country
- India
- Employees
- 8
- Sector
- General
- Sector Strength
- 55
- Industry
- Coal
Anmol India Ltd. Business Overview & Revenue Model
Company Description
Anmol India Limited is an Indian enterprise primarily involved in the commercial exchange of coal and related commodities. The company's product range features GCV coal, coal imported from the USA and Indonesia, and pet coke originating from Saudi Ar...
Anmol India Ltd. Financial Statement Overview
Summary
Mixed fundamentals: income statement shows strong multi-year revenue growth but thin and volatile margins; balance sheet risk is elevated due to volatile, often high leverage; cash flow is the biggest weakness with multiple years of deeply negative operating/free cash flow and only intermittent rebounds, reducing confidence in resilience and funding flexibility.
Income Statement
56NeutralBalance Sheet
41NeutralCash Flow
22Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.96B | 14.17B | 12.74B | 15.01B | 14.10B | 10.59B |
| Gross Profit | 203.10M | 209.20M | 197.10M | 335.65M | 313.97M | 259.18M |
| EBITDA | 238.30M | 289.80M | 256.70M | 341.45M | 321.05M | 275.21M |
| Net Income | 115.20M | 113.00M | 69.90M | 212.20M | 186.57M | 155.55M |
Balance Sheet | ||||||
| Total Assets | 0 | 3.44B | 3.59B | 2.83B | 4.65B | 2.97B |
| Cash, Cash Equivalents and Short-Term Investments | 1.27B | 1.27B | 1.38B | 1.50B | 1.72B | 1.19B |
| Total Debt | 0 | 1.97B | 2.20B | 852.96M | 2.95B | 1.79B |
| Total Liabilities | -1.19B | 2.25B | 2.51B | 1.82B | 3.86B | 2.36B |
| Stockholders Equity | 1.19B | 1.19B | 1.07B | 1.01B | 791.14M | 603.97M |
Cash Flow | ||||||
| Free Cash Flow | 0 | 21.30M | -1.21B | 2.12B | -442.50M | -640.97M |
| Operating Cash Flow | 0 | 25.40M | -1.20B | 2.12B | -439.51M | -634.77M |
| Investing Cash Flow | 0 | 92.30M | -111.00M | -112.86M | -81.92M | -81.41M |
| Financing Cash Flow | 0 | -222.90M | 1.19B | -2.23B | 1.06B | 1.31B |
Anmol India Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ANMOL, the sentiment is Negative. The current price of 11.02 is below the 20-day moving average (MA) of 11.91, below the 50-day MA of 12.10, and below the 200-day MA of 11.59, indicating a bearish trend. The MACD of -0.45 indicates Positive momentum. The RSI at 37.10 is Neutral, neither overbought nor oversold. The STOCH value of 20.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ANMOL.
Anmol India Ltd. Peers Comparison
Overall Rating
IN:ANMOL58Neutral
IN:JHS57Neutral
IN:AMBICAAGAR52Neutral
IN:VIVIMEDLAB40Underperform
IN:FCONSUMER37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 58Neutral | INR 627.19M | 5.51 | ― | ― | -2.63% | 32.25% | |
| 57Neutral | INR 702.74M | -36.32 | ― | ― | 19.41% | 90.12% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 52Neutral | INR 402.47M | 13.80 | ― | ― | 3.70% | 574.64% | |
| 40Underperform | INR 506.60M | -0.26 | ― | ― | -39.80% | -452.04% | |
| 37Underperform | INR 459.32M | -1.35 | ― | ― | 7.54% | 4.37% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:ANMOL | Anmol India Ltd. | 11.02 | -4.57 | -29.31% | |
| IN:AMBICAAGAR | Ambica Agarbathies & Aroma Industries Ltd. | 23.43 | -2.27 | -8.83% | |
| IN:FCONSUMER | Future Consumer Limited | 0.23 | -0.19 | -45.24% | |
| IN:GOLDENTOBC | Golden Tobacco Limited | 22.00 | -11.90 | -35.10% | |
| IN:JHS | JHS Svendgaard Laboratories Limited | 8.04 | -4.86 | -37.67% | |
| IN:VIVIMEDLAB | Vivimed Labs Limited | 6.11 | 1.21 | 24.69% |
Anmol India Ltd. Corporate Events
Anmol India Confirms Full Demat Compliance Under SEBI Regulation 74(5)
Anmol India Limited has notified stock exchanges that it has obtained a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30 September 2026. The certificate was issued b...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 16, 2026